OTCPK:CBII.F

Stock Analysis Report

Executive Summary

CB2 Insights Inc. provides predictive analytics tools, data-driven software, and comprehensive services for the cannabis value chain industry the United States, Canada, and internationally.

Snowflake

Fundamentals

Overvalued with weak fundamentals.

Risks

  • CB2 Insights has significant price volatility in the past 3 months.
  • CB2 Insights is not covered by any analysts.

Share Price & News

How has CB2 Insights's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.5%

OTCPK:CBII.F

-0.003%

US Healthcare Services

-0.02%

US Market


1 Year Return

n/a

OTCPK:CBII.F

8.6%

US Healthcare Services

1.6%

US Market

No trading data on CBII.F.

No trading data on CBII.F.


Share holder returns

CBII.FIndustryMarket
7 Day-10.5%-0.003%-0.02%
30 Day-13.5%-5.0%2.7%
90 Day-30.8%-5.6%1.4%
1 Yearn/a8.7%8.6%3.8%1.6%
3 Yearn/a49.3%49.0%45.2%35.8%
5 Yearn/a49.4%48.5%61.8%44.1%

Price Volatility Vs. Market

How volatile is CB2 Insights's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CB2 Insights undervalued based on future cash flows and its price relative to the stock market?

1.59x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for CB2 Insights to establish if it is available at moderate discount.

Unable to calculate intrinsic value for CB2 Insights to establish if it is available at substantial discount.


Price Based on Earnings

CB2 Insights is loss making, we can't compare its value to the US Healthcare Services industry average.

CB2 Insights is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CB2 Insights, we can't assess if its growth is good value.


Price Based on Value of Assets

CB2 Insights is good value based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is CB2 Insights expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CB2 Insights has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CBII.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access CB2 Insights's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has CB2 Insights performed over the past 5 years?

-64.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CB2 Insights does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare CB2 Insights's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CB2 Insights's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CB2 Insights has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CB2 Insights has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CB2 Insights improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CB2 Insights's financial position?


Financial Position Analysis

CB2 Insights's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

CB2 Insights's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

CB2 Insights's level of debt (62.9%) compared to net worth is high (greater than 40%).

Unable to establish if CB2 Insights's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

CB2 Insights has less than a year of cash runway based on current free cash flow.

CB2 Insights has less than a year of cash runway if free cash flow continues to grow at historical rates of 69.8% each year.


Next Steps

Dividend

What is CB2 Insights's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CB2 Insights's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CB2 Insights's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CB2 Insights has not reported any payouts.

Unable to verify if CB2 Insights's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CB2 Insights has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CB2 Insights's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Prad Sekar 0

0yrs

Tenure

0

Mr. Pradyum Sekar, also known as Prad, serves as Chief Executive Officer, Co-Founder and Secretary at CB2 Insights Inc. and serves as its Executive Director since February 27, 2019. 


Management Age and Tenure

0.6yrs

Average Tenure

The average tenure for the CB2 Insights management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.4yrs

Average Tenure

The average tenure for the CB2 Insights board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyCA$12217 Sep 19
Pradyum Sekar
EntityIndividual
Role
Chief Executive Officer
CEO, Co-Founder
Shares1,102
Max PriceCA$0.11
BuyCA$80417 Sep 19
Kashaf Qureshi
EntityIndividual
Role
Member of the Board of Directors
President
Shares7,948
Max PriceCA$0.11
BuyCA$2,48003 Jun 19
Norton Singhavon
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceCA$0.25

Ownership Breakdown


Management Team

  • Carm Marrelli (48yo)

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Kash Qureshi

    President

    • Tenure: 0.6yrs
  • Prad Sekar

    CEO, Co-Founder

    • Tenure: 0yrs
  • Dan Thompson

    Chief Corporate Officer

    • Tenure: 0.08yrs
  • Kishan Mahabir

    Chief Medical Officer

    • Tenure: 0.7yrs

Board Members

  • David Danziger (62yo)

    Chairman of the Board

    • Tenure: 0.3yrs
  • Gerry Goldberg (75yo)

    Director

    • Tenure: 0.08yrs
  • Norton Singhavon

    Director

    • Tenure: 0.6yrs
  • Kash Qureshi

    President

    • Tenure: 0.6yrs
  • Prad Sekar

    CEO, Co-Founder

    • Tenure: 0yrs
  • Marc Adelson

    Director

    • Tenure: 0.4yrs
  • Peter Cummins

    Director

    • Tenure: 0.2yrs

Company Information

CB2 Insights Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CB2 Insights Inc.
  • Ticker: CBII.F
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: CA$10.891m
  • Listing Market Cap: CA$8.207m
  • Shares outstanding: 83.78m
  • Website: https://cb2insights.com

Location

  • CB2 Insights Inc.
  • 5045 Orbitor Drive
  • Building 11
  • Mississauga
  • Ontario
  • L4W 4Y4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBIICNSX (Canadian National Stock Exchange)YesClass A Common SharesCACADMar 2019
CBII.FOTCPK (Pink Sheets LLC)YesClass A Common SharesUSUSDMar 2019

Biography

CB2 Insights Inc. provides predictive analytics tools, data-driven software, and comprehensive services for the cannabis value chain industry the United States, Canada, and internationally. The company dev ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 01:14
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.